JP2011528913A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011528913A5 JP2011528913A5 JP2011520375A JP2011520375A JP2011528913A5 JP 2011528913 A5 JP2011528913 A5 JP 2011528913A5 JP 2011520375 A JP2011520375 A JP 2011520375A JP 2011520375 A JP2011520375 A JP 2011520375A JP 2011528913 A5 JP2011528913 A5 JP 2011528913A5
- Authority
- JP
- Japan
- Prior art keywords
- mutant
- factor
- amino acid
- acid substitution
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 238000006467 substitution reaction Methods 0.000 claims 24
- 102100022641 Coagulation factor IX Human genes 0.000 claims 18
- 108010076282 Factor IX Proteins 0.000 claims 17
- 229960004222 factor ix Drugs 0.000 claims 17
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 208000031169 hemorrhagic disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 102220160314 rs886062844 Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102200147804 rs193929360 Human genes 0.000 claims 3
- 108010048049 Factor IXa Proteins 0.000 claims 2
- 108010054218 Factor VIII Proteins 0.000 claims 2
- 102000001690 Factor VIII Human genes 0.000 claims 2
- 108010061932 Factor VIIIa Proteins 0.000 claims 2
- 208000009292 Hemophilia A Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 206010073391 Platelet dysfunction Diseases 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229960000301 factor viii Drugs 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 102220048271 rs587784390 Human genes 0.000 claims 2
- 102220034170 rs75368761 Human genes 0.000 claims 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 102100023804 Coagulation factor VII Human genes 0.000 claims 1
- 102100026735 Coagulation factor VIII Human genes 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 108010014172 Factor V Proteins 0.000 claims 1
- 108010023321 Factor VII Proteins 0.000 claims 1
- 201000003542 Factor VIII deficiency Diseases 0.000 claims 1
- 108010014173 Factor X Proteins 0.000 claims 1
- 108010074864 Factor XI Proteins 0.000 claims 1
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 claims 1
- 208000027276 Von Willebrand disease Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 230000010100 anticoagulation Effects 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 238000002659 cell therapy Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000013613 expression plasmid Substances 0.000 claims 1
- 229940012413 factor vii Drugs 0.000 claims 1
- 208000009429 hemophilia B Diseases 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000005030 transcription termination Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 108010047303 von Willebrand Factor Proteins 0.000 claims 1
- 208000012137 von Willebrand disease (hereditary or acquired) Diseases 0.000 claims 1
- 102100036537 von Willebrand factor Human genes 0.000 claims 1
- 229960001134 von willebrand factor Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08013561A EP2149603A1 (en) | 2008-07-28 | 2008-07-28 | Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders |
| EP08013561.9 | 2008-07-28 | ||
| PCT/EP2009/005465 WO2010012451A1 (en) | 2008-07-28 | 2009-07-28 | Factor ix variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011528913A JP2011528913A (ja) | 2011-12-01 |
| JP2011528913A5 true JP2011528913A5 (enExample) | 2012-09-20 |
| JP6029826B2 JP6029826B2 (ja) | 2016-11-24 |
Family
ID=40032573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011520375A Active JP6029826B2 (ja) | 2008-07-28 | 2009-07-28 | 補因子の非存在下において凝固活性を有する第ｉｘ因子変異体および出血性疾患の処置のためのその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US10125357B2 (enExample) |
| EP (6) | EP2149603A1 (enExample) |
| JP (1) | JP6029826B2 (enExample) |
| KR (2) | KR101768896B1 (enExample) |
| CN (1) | CN102112608B (enExample) |
| AU (1) | AU2009275391B2 (enExample) |
| CA (2) | CA3033578C (enExample) |
| ES (3) | ES2441167T3 (enExample) |
| WO (1) | WO2010012451A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3581650T3 (fi) | 2008-09-15 | 2023-03-23 | Uniqure Biopharma B V | IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi |
| TWI595004B (zh) | 2010-11-03 | 2017-08-11 | 介控生化科技公司 | 經修飾之第九因子多胜肽及其用途 |
| RU2013142015A (ru) | 2011-03-02 | 2015-04-10 | Ново Нордиск А/С | Нацеливание факторов свертывания крови на рецептор tlt-1 на поверхности активированных тромбоцитов |
| WO2013016454A1 (en) * | 2011-07-25 | 2013-01-31 | Biogen Idec Hemophilia Inc. | Assays to monitor bleeding disorders |
| CN103173482A (zh) * | 2011-12-22 | 2013-06-26 | 武汉科技大学 | 野生型和突变体hFⅨ毕赤酵母表达载体及构建方法和应用 |
| EP2666782A1 (en) * | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
| US20150337284A1 (en) * | 2012-10-29 | 2015-11-26 | Regents Of The University Of Minnesota | Factor ix variants |
| CN103060366A (zh) * | 2012-12-25 | 2013-04-24 | 武汉科技大学 | 人凝血因子ⅸ突变体毕赤酵母表达载体及构建方法和应用 |
| FI3889173T3 (fi) | 2013-02-15 | 2023-10-02 | Bioverativ Therapeutics Inc | Optimoitu tekijä viii:n geeni |
| US9651567B2 (en) * | 2013-05-14 | 2017-05-16 | Cgt Enterprises, Llc | Test strips for determining coagulation factor activities |
| EP2881463A1 (en) | 2013-12-09 | 2015-06-10 | DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH | Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders |
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| GB201420139D0 (en) | 2014-11-12 | 2014-12-24 | Ucl Business Plc | Factor IX gene therapy |
| US11066481B2 (en) | 2015-07-23 | 2021-07-20 | The Regents Of The University Of California | Antibodies to coagulation factor XIa and uses thereof |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| KR20240170979A (ko) | 2017-07-10 | 2024-12-05 | 유니큐어 아이피 비.브이. | 인간에서의 ａａｖ 유전자 요법을 위한 수단 및 방법 |
| US10842885B2 (en) | 2018-08-20 | 2020-11-24 | Ucl Business Ltd | Factor IX encoding nucleotides |
| GB201813528D0 (en) | 2018-08-20 | 2018-10-03 | Ucl Business Plc | Factor IX encoding nucleotides |
| GB201817810D0 (en) * | 2018-10-31 | 2018-12-19 | Ucl Business Plc | Modified factor IX polypeptides |
| WO2020104480A1 (en) * | 2018-11-19 | 2020-05-28 | Uniqure Biopharma B.V. | Adeno-associated virus vectors for expressing fviii mimetics and uses thereof |
| AU2020242945B2 (en) | 2019-03-19 | 2025-06-26 | CSL Innovation Pty Ltd | Factor IX variants and uses thereof in therapy |
| CN110684798A (zh) * | 2019-09-03 | 2020-01-14 | 深圳新诺微环生物科技有限公司 | 肌肉靶向的微环dna基因治疗 |
| US12403164B2 (en) | 2019-09-30 | 2025-09-02 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| KR20230074703A (ko) | 2020-06-24 | 2023-05-31 | 바이오버라티브 테라퓨틱스 인크. | 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법 |
| CN114277057B (zh) * | 2021-07-09 | 2023-10-13 | 上海天泽云泰生物医药有限公司 | 用于治疗或预防b型血友病的重组腺相关病毒载体和方法 |
| EP4423119A1 (en) | 2021-10-27 | 2024-09-04 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for expressing factor ix for hemophilia b therapy |
| US20250242056A1 (en) | 2024-01-26 | 2025-07-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing |
| WO2025184567A1 (en) | 2024-03-01 | 2025-09-04 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| WO1999003496A1 (en) * | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| EP1282438B1 (en) | 2000-05-10 | 2005-08-03 | Novo Nordisk Health Care AG | Use of pharmaceutical composition comprising a factor viia and a factor xiii |
| RU2326126C2 (ru) * | 2000-09-13 | 2008-06-10 | Ново Нордиск Хелт Кэр Аг | Полипептид фактора vii свертывания крови, его получение и применение |
| US7125841B2 (en) | 2000-11-14 | 2006-10-24 | The University Of Texas Systems | Mutant human factor IX with an increased resistance to inhibition by heparin |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| BRPI0514396A2 (pt) * | 2004-08-17 | 2009-05-12 | Csl Behring Gmbh | polipeptìdeos dependentes de vitamina k modificada |
| WO2007149406A2 (en) * | 2006-06-19 | 2007-12-27 | Nautilus Technology Llc | Modified coagulation factor ix polypeptides and use thereof for treatment |
| US7700734B2 (en) * | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
| CA2674879A1 (en) * | 2007-02-01 | 2008-08-07 | Baxter International Inc. | Improved fix-mutant proteins for hemophilia b treatment |
| US8022187B2 (en) * | 2007-02-01 | 2011-09-20 | Baxter International Inc. | FVIII-independent FIX-mutant proteins for hemophilia A treatment |
| DE102008034724A1 (de) * | 2008-07-25 | 2010-01-28 | Alexander Koslow | Verkugelungs- / Zerkleinerungsmaschine |
-
2008
- 2008-07-28 EP EP08013561A patent/EP2149603A1/en not_active Withdrawn
-
2009
- 2009-07-28 EP EP17164245.7A patent/EP3241899B1/en active Active
- 2009-07-28 JP JP2011520375A patent/JP6029826B2/ja active Active
- 2009-07-28 CA CA3033578A patent/CA3033578C/en active Active
- 2009-07-28 WO PCT/EP2009/005465 patent/WO2010012451A1/en not_active Ceased
- 2009-07-28 EP EP14165396.4A patent/EP2767587B1/en active Active
- 2009-07-28 CN CN2009801296698A patent/CN102112608B/zh active Active
- 2009-07-28 EP EP19191719.4A patent/EP3623470A3/en not_active Withdrawn
- 2009-07-28 KR KR1020117001765A patent/KR101768896B1/ko active Active
- 2009-07-28 US US13/001,187 patent/US10125357B2/en active Active
- 2009-07-28 ES ES11005215.6T patent/ES2441167T3/es active Active
- 2009-07-28 ES ES14165396.4T patent/ES2628688T3/es active Active
- 2009-07-28 EP EP09777493A patent/EP2318526A1/en not_active Ceased
- 2009-07-28 ES ES17164245T patent/ES2753638T3/es active Active
- 2009-07-28 EP EP11005215.6A patent/EP2390323B1/en active Active
- 2009-07-28 AU AU2009275391A patent/AU2009275391B2/en not_active Ceased
- 2009-07-28 CA CA2729501A patent/CA2729501C/en active Active
- 2009-07-28 KR KR1020177022245A patent/KR101947424B1/ko active Active
-
2018
- 2018-10-01 US US16/148,819 patent/US10883097B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Linden et al. | Platelets: pleiotropic roles in atherogenesis and atherothrombosis | |
| Schober et al. | SDF-1α-mediated tissue repair by stem cells: a promising tool in cardiovascular medicine? | |
| JP6002727B2 (ja) | 末梢循環への骨髄由来多能性幹細胞動員薬 | |
| JP2012126750A5 (enExample) | ||
| JP5037331B2 (ja) | 出血性障害の処置のための第ｉｘａ因子 | |
| EA029560B1 (ru) | Применение химерного фактора свертывания крови для уменьшения ингибирующего иммунного ответа у субъекта | |
| US20120164111A1 (en) | Novel post-translational fibrinogen variants | |
| JP2010530238A5 (enExample) | ||
| JP2003530093A5 (enExample) | ||
| EP2858659A1 (en) | Procoagulant compounds | |
| JP2014113157A5 (enExample) | ||
| JP2004180682A (ja) | 改変第ＶＩＩＩ因子ｃＤＮＡおよびその誘導体 | |
| JP2017505114A5 (enExample) | ||
| ES2938890T3 (es) | Proteínas de fusión de VWF glucosiladas con farmacocinética mejorada | |
| AU2007223880A1 (en) | A method for the preparation of recombinant human thrombin and fibrinogen | |
| BR112015012854B1 (pt) | Método para purificar proteínas selecionadas do grupo consistindo em plasminogênio, ativador do plasminogênio tecidual e outra(s) protease(s), solução compreendendo fibrinogênio e/ou fator viii e/ou vwf, seu uso e formulação farmacêutica | |
| WO2018042438A2 (en) | Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders | |
| JP2007521294A5 (enExample) | ||
| EP1987063B1 (en) | Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | |
| CN114929735A (zh) | 因子viii构建体 | |
| CN111770767A (zh) | 用于从生物流体中去除纤溶蛋白的体外设备和基质、其方法和用途 | |
| JP2008545393A (ja) | 進歩したインターフェロンαポリペプチド | |
| Luyendyk et al. | Factor XIII: driving (cross-) links in hemostasis, thrombosis, and disease | |
| WO2007101106A2 (en) | Compositions and methods for modulating hemostasis using variant forms of activated factor v | |
| ES2708675T3 (es) | Mutante de GDF-5 para inducir la formación de cartílago |